Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1…
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to…
Toronto, Ontario--(Newsfile Corp. - August 9, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) ("FSD Pharma" or…
Financials for First Quarter of Fiscal Year 2025 Ended June 30, 2024 will be released on August 14, 2024Northvale, New…
WOBURN, MA / ACCESSWIRE / August 9, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of…
TORONTO, ON / ACCESSWIRE / August 9, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update on its…
Vancouver, British Columbia--(Newsfile Corp. - August 9, 2024) - Celly Nutrition Corp. ("Celly Nu" or the "Company"), which is backed…
Ginkgo provides update on its restructuring process including estimated annualized cost savings of over $85 million from reduction in force …
Kristin Judge assumes leadership role for all commercial functions WILMINGTON, N.C., Aug. 8, 2024 /PRNewswire/ -- Catalyst Clinical Research announced today…
DENVER, CO / ACCESSWIRE / August 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical…